Evelo Biosciences, Inc. Common Stock
EVLO
EVLO was delisted on the 11th of December, 2023.
47 hedge funds and large institutions have $200M invested in Evelo Biosciences, Inc. Common Stock in 2020 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 23 increasing their positions, 8 reducing their positions, and 3 closing their positions.
188% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 8
167% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 3
86% more capital invested
Capital invested by funds: $108M → $200M (+$92.2M)
12% more funds holding
Funds holding: 42 → 47 (+5)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FP
Flagship Pioneering
Cambridge,
Massachusetts
|
+$20.4M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$5.82M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$5.69M |
| 4 |
HP
Harbourvest Partners
Boston,
Massachusetts
|
+$5.69M |
| 5 |
EC
EcoR1 Capital
San Francisco,
California
|
+$5.47M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
-$334K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$284K |
| 3 |
Bank of New York Mellon
New York
|
-$41.5K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$38K |
| 5 |
Nuveen
Charlotte,
North Carolina
|
-$18.4K |
EVLO Hedge Fund Activity: Q2 2020 in Review
47 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Evelo Biosciences, Inc. Common Stock (EVLO) for Q2 2020, worth a combined $200M — up 86% from $108M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new EVLO positions and 3 closed out — a net gain of 5 holders — while 23 added to existing stakes and 8 trimmed.
The largest buyer was Flagship Pioneering, adding an estimated $20.4M. The largest seller was Victory Capital Management, exiting entirely with an estimated $334K sold.
- 47 institutional investors held Evelo Biosciences, Inc. Common Stock (EVLO) as of Q2 2020, up from 42 in Q1 2020.
- Funds reported $200M of Evelo Biosciences, Inc. Common Stock stock for Q2 2020, up 86% quarter-over-quarter.
- 8 funds opened new Evelo Biosciences, Inc. Common Stock positions in Q2 2020 and 3 closed out, a net change of +5 holders.
- The largest Evelo Biosciences, Inc. Common Stock buyer in Q2 2020 was Flagship Pioneering, an estimated $20.4M added.
- The largest Evelo Biosciences, Inc. Common Stock seller in Q2 2020 was Victory Capital Management, an estimated $334K sold.
Based on aggregated 13F filings for Q2 2020.